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The acronym VATER/VACTERL association describes the combination of at least three of the following congenital anomalies:
vertebral defects (V), anorectal malformations (A), cardiac defects (C), tracheoesophageal fistula with or without esophageal
atresia (TE), renal malformations (R), and limb defects (L). We aimed to identify highly penetrant de novo copy number
variations (CNVs) that contribute to VATER/VACTERL association. Array-based molecular karyotyping was performed in a cohort
of 41 patients with VATER/VACTERL association and 6 patients with VATER/VACTERL-like phenotype including all of the
patients’ parents. Three de novo CNVs were identified involving chromosomal regions 1q41, 2q37.3, and 8q24.3 comprising
one (SPATA17), two (CAPN10, GPR35), and three (EPPK1, PLEC, PARP10) genes, respectively. Pre-existing data from the
literature prompted us to choose GPR35 and EPPK1 for mouse expression studies. Based on these studies, we prioritized
GPR35 for sequencing analysis in an extended cohort of 192 patients with VATER/VACTERL association and VATER/VACTERL-
like phenotype. Although no disease-causing mutation was identified, our mouse expression studies suggest GPR35 to be
involved in the development of the VATER/VACTERL phenotype. Follow-up of GPR35 and the other genes comprising the
identified duplications is warranted.
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INTRODUCTION
The VATER/VACTERL association (OMIM #192350) refers to
the rare, non-random co-occurrence of the following component
features (CFs): vertebral defects (V), anorectal malformations (A),
cardiac defects (C), tracheoesophageal fistula with or without
esophageal atresia (TE), renal malformations (R), and limb defects
(L).1 Population-based epidemiological studies have reported a
prevalence among infants of 1 in 10000 to 1 in 40 000 with male
predominance.2–4 Since this multisystem malformation complex has
been associated with reduced reproduction, it is reasonable to assume
that a significant proportion of cases are caused by de novomutations.
In accordance with this, previous studies have identified several de
novo chromosomal microaberrations, which are likely to be disease
causing.5–16 However, none of these de novo chromosomal
microaberrations has led to the identification of a disease-causing
gene and the etiology in most cases is still unknown.
Using a SNP-array-based genome-wide approach, we systematically
screened 41 patients with VATER/VACTERL association and
6 patients with a VATER/VACTERL-like phenotype, including all of
the patients’ parents, in order to identify causative de novo copy
number variations (CNVs). Pre-existing data from the literature were
used to choose candidate genes within the identified CNVs for in situ
hybridization (ISH) on sections from mouse embryos at embryonic
days (E) 12.514.5. Based on the ISH, candidate genes were
prioritized for sequencing analysis in an extended cohort of 192
patients with VATER/VACTERL association and VATER/VACTERL-
like phenotype in order to identify further disease-causing mutations.
MATERIALS AND METHODS
Subjects and DNA isolation
This study was approved by the local ethics committee and all families
provided written informed consent. Families were contacted through the
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German self-help organization for patients with anorectal malformations
(SoMA e.V.) and various pediatric surgical departments throughout Germany.
Among the patients was one aborted female fetus, enrolled through the
Department of Paidopathology, University of Bonn. All patients and their
families were personally recruited by one of four experienced physicians
starting in 2009. None of the patients used for array-based analysis has been
reported in our previous studies.15,16 To optimize for detection of de novo
CNVs, we only included patients with a negative family history of the disease.
Forty-one patients presented with three or more CFs of the VATER/VACTERL
association, while six patients presented with only two, with or without further
anomalies (VATER/VACTERL-like phenotype).1 For the mutation-sequencing
analysis, an additional 59 patients with VATER/VACTERL association and 60
patients with VATER/-VACTERL-like phenotype recruited within Germany
were added to the patient sample, of which 18 patients were previously
described in Schramm et al.15,16 An additional 26 patients with VATER/
VACTERL association were recruited within the AGORA project and were
added to the sample for the mutation-sequencing analysis. The AGORA
project is run within the Netherlands and patients are being recruited
by pediatric surgeons and clinical geneticists of the Radboud University,
Nijmegen Medical Centre, Nijmegen, the Netherlands. The complete sample
for mutation-sequencing analysis comprised 192 patients (n¼ 132 patients
with VATER/VACTERL association; n¼ 60 patients with VATER/-VACTERL-
like phenotype). As all of the recruited patients in Germany and the
Netherlands were part of research projects on the genetics of anorectal
malformations, all patients had anorectal malformations. Blood or saliva was
taken from the patient and from both parents for DNA isolation of genomic
DNA, carried out using the Chemagic Magnetic Separation Module I
(Chemagen, Baesweiler, Germany) or, in case of saliva samples, the Oragene
DNA Kit (DNA Genotek Inc., Kanata, ON, Canada).
Array genomic hybridization analysis
For molecular karyotyping, we used the Illumina HumanOmni1-Quad-v1
BeadChip (marker content, 1 140 419; median marker spacing 1.5 kb) (San
Diego, CA, USA). A DNA sample was considered to have failed if less than
98% of the markers were generated on the respective BeadChip.
Paternity testing
Paternity testing was performed using the GenomeStudio (v2010.3, www.
illumina.com/) genotyping module in accordance with the manufacturer’s
recommendations.
CNV analysis
To identify potential CNVs, the SNP fluorescence intensity data from all
patients and their parents were analyzed with QuantiSNP (v2.1 and v2.2,
www.well.ox.ac.uk/QuantiSNP/) using an Objective Bayes Hidden-Markov
model for calling putative CNVs.17 CNVs with a log Bayes factor below 7
were discarded.18 The results were also checked visually using the
GenomeStudio genotyping module (v2010.3, www.illumina.com/) for
marker and signal quality and the occurrence of mosaic aberrations. The
Cartagenia Bench software (Cartagenia n.v., Leuven, Belgium) was used to
filter detected CNVs for de novo events, variable regions in our control cohort
of 531 unaffected controls, and gene content. The remaining aberrations
were checked for gene content according to UCSC human genome
browser assembly build 18, and for their presence in the databases DGV
(http://dgvbeta.tcag.ca/dgv/app/home?ref=NCBI36/hg18) and DECIPHER
(http://decipher.sanger.ac.uk/). CNVs identified to exist in either of these
databases, with at least 10 full overlapping reports in DGV and at least five full
overlapping reports in DECIPHER, were excluded. However, we did not
exclude CNVs although they were fully overlapping by at least five reports in
DECIPHER, if one of the associated phenotypes comprised any of the classical
component features of the VATER/VACTERL association: e.g. esophageal
atresia (TE), anorectal malformation (A), cardiac defects (C).
Quantitative PCR
For verification of the filtered CNVs, qPCR was performed as described
previously using SYBR Green for detection.19 All primer sequences are listed in
Supplementary Table 2.
In situ hybridization of mouse embryo sections
To prioritize candidate genes within the remaining CNVs for further mutation
analysis in larger patient cohorts, ISH on sections from mouse embryos at
E12.5–14.5, the crucial embryonic timeframe for the VATER/VACTERL
association-relevant tissues, was performed as previously described.20
Antisense probes were generated by PCR from a total cDNA library from
E10.5 where PCR products contained a 30 T7 RNA polymerase-binding site for
in vitro transcription. Probes were purified using G-50 Sephadex columns
(GE Healthcare, Munich, Germany). The 903-bp probe for Gpr35 (starting
13 bp downstream of the ATG start site) spans nearly the entire 924-bp coding
region and recognizes both known mRNA variants. Eppk1 is encoded by a
single, large exon (420kb) consisting of 16 plakin repeat domains, which are
the hallmark of all plakin family members.21 Thus, the unique 647-bp probe
for Eppk1 spans the 30UTR. Detection of alkaline phosphatase activity was
visualized using BM Purple (Roche Diagnostics, Mannheim, Germany).
Following staining, slides were quickly dehydrated in 80% and then 100%
ethanol, cleared twice for 1min in xylene (Roth, Karlsruhe, Germany) and
coverslips were mounted with Entellan mounting medium (Merck, Darmstadt,
Germany). Photographs were obtained using AxioVision software (Zeiss,
Go¨ttingen, Germany) with a Zeiss AxioCam and SteREO DiscoveryV12
microscope. Three sections from at least two different embryos were
analyzed for each stage shown and representative images are provided.
Sequence analysis
Analysis of the protein-coding exons 5 and 6 of the human GPR35 gene was
performed using polymerase chain reaction (PCR), and PCR-amplified DNA
products were subjected to direct automated sequencing (3130XL Genetic
Analyzer, Applied Biosystems, Foster City, CA, USA) according to the
manufacturer’s specifications. Both strands of each amplicon were sequenced.
All primer sequences are available upon request.
RESULTS
Array analysis
Molecular karyotyping identified five possible de novo aberrations
with gene content in five of the 47 patients. Three of these were
confirmed as being de novo by qPCR (Table 1, Supplementary
Tables 1 and 2, and Supplementary Figure), the others were found
to be inherited by one parent (see Supplementary Tables 1 and 2).
In the three confirmed cases, there were no other dysmorphic
features, congenital anomalies (including structural brain anomalies
or evidence of neurologic impairment), or other medical issues except
those noted below.
Case 1 is a male patient with butterfly vertebra (V), anal atresia
without fistula (A), atrial and ventricular septal defects (C), esopha-
geal atresia IIIb (according to Vogt)22 (TE), bilateral dystopic kidneys,
and left-sided renal dysplasia (R). A de novo microduplication was
found at 1q41 (Table 1) with an estimated size of 132 kb, comprising
exons 6–9 of SPATA17, encoding the spermatogenesis-associated
protein 17.
Case 2 is an aborted female fetus. The pregnancy was terminated at
30þ 1 weeks of gestation because of sonographically proven severe
bilateral renal dysplasia. Macroscopic and histological findings
obtained at autopsy revealed a cloacal malformation with anal atresia
(A), bilateral renal dysplasia (R), urethral agenesis, a secondary bell-
shaped thorax, and Potter-sequence facies due to anhydramnion
(Figure 1). A de novo microduplication was found at 2q37.3 (Table 1)
with an estimated size of 25 kb, comprising exons 3–4 of one splice
variant of Calpain-10 (CAPN10) and exons 3–6 of GPR35, encoding
the G-protein-coupled receptor 35.
Case 3 is a male patient with butterfly vertebra (V), anal atresia
with recto-vesical fistula (A), congenital subvalvular aortic stenosis
and ventricular septal defect (C), esophageal atresia IIIb (according to
Vogt)22 (TE), high-grade bilateral vesico-ureteral reflux (III1 and IV1)
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(R), and bilateral cryptorchidism. A de novo microduplication was
found at 8q24.3 (Table 1) with an estimated size of 120 kb. This
region comprises parts of exon 1 of the epiplakin gene (EPPK1), the
complete plectin-1 gene (PLEC-1), and exons 4–11 of the gene coding
for poly(ADP-ribose)polymerase 10 (PARP10).
CNVs found in DGV with partial overlap of the three duplicated
regions of interest (1q41, 2q37.3, 8q24.3) are listed in Supplementary
Table 3. In DECIPHER, no partially but only fully overlapping CNVs
were found. Interestingly, the duplicated region 8q24.3 found in case
3 contains partially overlapping CNVs more frequently than the other
duplications, most likely due to the adjacent repeat elements mapping
to the boundaries of this region.
Gene prioritization and ISH analysis
A database search on expression data and targeted deletions in mice
for the genes Spata17, Capn10, Gpr35, Eppk1, Plec1, and Parp10
using the Mouse Genome Informatics (MGI) database was performed
to narrow down the candidate gene list. Entries provide expression
data from the Eurexpress project23 freely available from the Jackson
Laboratory Mouse Genome Informatics database (http://www.
informatics.jax.org/). As expression of Spata17, which encodes a
protein related to apoptosis of spermatogenic cells, is restricted to
the testis in several species,24,25 it was not given high priority for
follow-up. The expression of Capn10 coding for a member of the
calpain-like cysteine protease family is moderate and ubiquitous at
E14.5. Targeted deletion of Capn10 resulted in viable mice showing
increased adiposity and metabolic defects26 in the homozygous state.
Hence, it was not given high priority. Plectin-1 interlinks intermediate
filaments with microtubules and microfilaments, and MGI expression
data on Plec1 during development were limited to the retina after
E14.0, but are likely to be elsewhere also, considering homozygous
knockout embryos exhibiting neonatal death with skin blistering and
defects in integument.27 Mutations in PLEC1 in human have been




























































































































































































































































































































































































































































































Figure 1 Anal atresia and genital malformations of case 2, a female fetus
also presenting with a cloacal malformation with anal atresia (A), bilateral
renal dysplasia (R), urethral agenesis, a secondary bell-shaped thorax, and
Potter-sequence facies due to anhydramnion.
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spectrum.28 No expression data were found for Parp10, but this gene
shares some common exons with Plec1.29 In their studies of targeted
deletion of Plec1, Fuchs et al,29 as a consequence of exon sharing
between Plec1 and Parp10, generate a P1c/ mouse line that
represents in fact a double knockout (P1c//Parp10/).
Although this targeted homozygous deletion was found to affect the
nervous system and the motor nerve conduction velocity of the mice
model investigated, it can be ruled out that this was due to the
targeted deletion of Parp10, as the conditional nes-Cre/plecf/D mouse
model (where plectin was knocked down, leaving Parp10 unaffected)
showed comparable phenotypes.29 Owing to the mouse expression
data in MGI and lack of congenital malformations in both
homozygous murine knockout models of Plec1 and Parp10, both
genes were not given high priority for follow-up.
The most promising candidates from the MGI expression data were
found to be Gpr35 and Eppk1. GPR35 is a member of the G-protein-
coupled receptor superfamily of transmembrane proteins involved in
a variety of physiological pathways. Previous studies showed expres-
sion of GPR35 in tissues of the gastrointestinal tract, nervous system,
and lymphoid tissues. It was reported that kynurenic acid might be an
endogenous ligand for GPR35,30 but more recent data suggested
lysophosphatidic acid (specifically 2-oleoyl LPA) to be a more likely
candidate.31 As Oka et al31 suggested that RhoA signaling might be
activated downstream of GPR35 (in vitro) and RhoA is involved in the
non-canonical planar cell polarity (PCP) pathway, it is tempting to
speculate that one role of GPR35 might be cell motility/polarity
during embryonic development. According to MGI, Gpr35 expression
has been detected at E14.5 within the stomach, hindgut, rectum,
Figure 2 Embryonic mouse expression of Eppk1 and Gpr35. (a) Eppk1 expression at E12.5 is detectable in the forebrain (fb), midbrain (mb), inner ear (ie),
liver (li), nasal passage (np), genital tubercle (gt), dorsal root ganglia (drg), and spinal cord (sc). (b) Eppk1 expression at E14.5 is detectable in the liver,
Rathke’s pouch (Rp), esophagus (e), corpus striatum mediale (csm), genital tubercle, tooth bud (tb), spinal cord, and nasal passages. (c) Gpr35 expression
at E12.5. Transcripts are evident in the liver, trigeminal ganglion (trg), vestibulocochlear ganglion (vcg), heart ventricle (h), stomach (st), mesonephros (me),
genital tubercle, dorsal root ganglia, and surrounding the maxillo-mandibular cleft (mmc). (d) Gpr35 expression at E14.5 is detectable in the liver, corpus
striatum mediale, hypothalamus (ht), tooth bud, lung (lu), genital tubercle, and rectum.
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midgut, bladder fundus region, and urethra. Eppk1 was expressed at
E14.5 in the epidermis, lung, and alimentary canal tissues, including
the stomach, esophagus, and gut. However, complete deletion of
Eppk1 results in normal embryonic development,32 whereas there is
currently no model for targeted deletion of Gpr35 in mice. According
to these pre-existing data, we decided to validate the expression
studies on Gpr35 and Eppk1 between E12.5–14.5, which is the
equivalent of human gestational weeks 6–8,33 encompassing the
relevant stages of development in mice for organ systems involved
in the etiology of VATER/VACTERL.
The expression of Eppk1 at E12.5 was found within the liver, oral
epithelium, nasal passages, brain, and neural tube. At E14.5, it was
additionally found in the developing tooth buds and esophageal
epithelium (Figure 2). Expression of Gpr35 at E12.5 was found in the
mesonephros, the heart, the esophagus and trachea, the dorsal root
ganglia, the genital tubercle, and the rectal region, and a similar
expression pattern was detected at E14.5 (Figure 2). This expression
not only reflected the affected organ systems of the patient/fetus
exhibiting the GPR35 comprising duplication but also showed
expression in tissues relevant to the VATER/VACTERL association in
general. Although the genital tubercle and the dorsal root ganglia do
not primarily belong to the tissues reflected by the CFs of the VATER/
VACTERL association, we point them out because a significant
proportion of patients present with genital anomalies/defects
arising from the genital tubercle.3 The neurons of the dorsal
root ganglia are closely affiliated with vertebral development and are
derived from the neural crest cells, which are involved in the formation
of tissues including the cardiac outflow tract and enteric nervous
system of the gut, suggesting a role in VATER/VACTERL association.
Candidate gene analysis
We further prioritized Gpr35 over Eppk1 as a result of both its
expression and available information in the literature, and carried out
mutation analysis of GPR35 in 192 VATER/VACTERL/VACTERL-like
patients. Sanger sequencing of the two protein-coding exons (exon 5
and 6) of GPR35 in these 192 patients (including case 2) did not
identify any sequence variant of likely pathological significance.
Heterozygous sequence variants with a minor allele frequency less
than 1% (rs139197368, rs35146537, rs201441371) were also checked
for their de novo status. They were found to be inherited by one
parent, with the exception of one sequence variant, where the father’s
DNA was not available for testing. Pathogenicity prediction with
four algorithms (PolyPhen-2, SNPs&Go, MutPred, SIFT) predicted
none of the three SNPs unanimously as disease causing. Two of these
variants have been predicted to be benign in all four prediction
algorithms applied. SNP rs201441371 leading to a p.Val237Met
substitution was classified as possibly disease causing in two and
benign in the other two pathogenicity-prediction algorithms. Hence,
incomplete penetrance cannot be excluded for this variant and should
warrant functional studies.
DISCUSSION
Although only a few large studies have been published, there are
several lines of evidence that de novo CNVs are associated with the
expression of structural birth defects.34 Depending on the investigated
birth defect, de novo CNVs have been assumed to be causative in up
to 20% of cases.35 In our study of patients with VATER/VACTERL
association and VATER/VACTERL-like phenotype, we identified three
(6%) likely causative de novo CNVs at 1q41, 2q37.3, and 8q24.3.
These CNVs contained between one and three genes, including
GPR35 and EPPK1, which are known, according to expression data
from MGI, to participate in the development of tissues relevant to the
VATER/VACTERL-like phenotype (Table 1). For candidate gene
mutation analysis, we prioritized GPR35 based on its expression in
mice in the rectal region, the genital tubercle, and the mesonephros,
showing a clear overlap with the malformed tissues in the duplica-
tion-carrying patient (case 2) (Figures 1 and 2). Sequence analysis of
the protein-coding exons did not identify any disease-causing muta-
tion. It is therefore unlikely that mutations affecting the GPR35 gene
are a frequent cause of VATER/VACTERL association; however, our
patient cohort might have been too small to detect rare causal
mutational events. Furthermore, we may have missed mutations by
not analyzing the non-protein-coding exons or the promoter region.
Yet, according to our mouse expression data reflecting both the
affected organ systems of the patient/fetus exhibiting the GPR35
comprising duplication and the tissues relevant to the VATER/
VACTERL association, GPR35 seems to be a promising candidate
gene being worth of further follow-up in genetic as well as functional
studies. Nevertheless, as we cannot exclude EPPK1, SPATA17,
CAPN10, PLEC1, or PARP10 as candidate genes, follow-up of these
genes is also warranted.
Our study did not investigate whether the identified microduplica-
tions alter the expression of the genes involved or lead to altered gene
products. This will require further studies. Particularly, in the case of a
negative effect on the gene function, there remains also the possibility
that the anomalies seen in patients are the results of autosomal-
recessive mutations, with one allele being altered by the de novo event
and the second allele being altered by an inherited change. We did
not exhaustively investigate this possibility. However, the lack of a
mutation in GPR35 in case 2 and the lack of GPR35 mutations in the
extended patients sample render this possibility unlikely for GPR35.
We can also not exclude the possibility that the expression of a gene
residing in a region flanking a microduplication could be affected by
means of a position effect. However, thorough screening of the
flanking regions failed to detect obvious candidate genes. Finally, it
remains possible that there were disease-associated CNVs among the
many inherited CNVs and that the full penetrance may only be
exerted by interaction with an environmental insult, as has been
recently demonstrated for hypoxia and fibroblast growth factor
signaling in the etiology of congenital scoliosis.36
In summary, a genome-wide analysis in patients with VATER/
VACTERL association or VATER/VACTERL-like phenotype has iden-
tified three potentially pathogenic CNVs affecting genes involved in
the development of the phenotype-relevant tissues. Although muta-
tion screening of the most promising candidate gene, GPR35, did not
confirm it as a frequent cause of the disorder, new insights were
gained and the identified variant loci warrant further evaluation.
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